Founded in 2018, Mesh Bio is a Singapore-based health tech company. The company was created by healthcare and technology veterans Andrew Wu, ArsenBatagov, and Dr. Melvin Heng to deliver cutting-edge digital solutions to address challenges in patient management and rising chronic diseases in the region. The company has raised $1.8 million in Seed funding.
The funding was led by deep tech investors Elev8.vc and Enterprise Singapore’s investment arm Seeds Capital, along with Citrine Capital and Tael Partners. Mesh Bio aims to use the funding to accelerate the rollout of Mesh Bio’s solution, DARA® – a predictive analytics and clinical workflow automation solution for healthcare providers – in Southeast Asia and Hong Kong. The funding will also be used to support clinical partnerships and collaborations.
“Our vision is to deliver cutting-edge digital solutions to address challenges in patient management and rising chronic diseases in the region. Through the support of Elev8.vc, Seeds Capital, Citrine Capital and Tael Partners, we see tremendous opportunity to help healthcare providers cope with the rise in cases and simultaneously, improve patient treatment and outcomes with DARA®,” said Andrew Wu, Mesh Bio Co-founder and CEO.
The company’s DARA® solution helps draw in real-time, multidimensional patient data, helping the physicians counsel patients and allowing patients to understand their laboratory reports and the diseases they live with.
Alodokter Raises Funding From MDI Ventures and Samsung Ventures Investment Corporation
Ahead of IPO, Delhivery raises $277 Million led by Fidelity Investments
Deutsche Bank Sets Up an ESG Centre of Excellence in Singapore
Liverpool FC Launches Second Retail Store in Singapore
Zenlayer Will Continue Expanding in SE Asia and South America, Raises $50M
© 2021 CIO Bulletin. All rights reserved.